Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin

Summary

Recombinant hirudin (r-hirudin) is a potent direct thrombin inhibitor with immunogenic properties. Anti-hirudin antibodies (aHAb) are detected in up to 74% of patients treated with r-hirudin for more than 5 days. aHAb may alter the pharmaco-kinetics and pharmacodynamics of r-hirudin.

The effects of aHAb on the pharmacokinetics of r-hirudin were investigated in rats receiving r-hirudin intravenously either without aHAb (controls), 15 min after intravenous administration of non-specific antibodies or aHAb, and after pre-incubation with aHAb. When both were compared to controls and pre-treatment with non-specific antibodies, aHAb significantly altered the pharmacokinetics of r-hirudin with similar effects in both approaches: In the presence of aHAb, the volume of distribution in a steady state and total plasma clearance were diminished, while the half-life of elimination was prolonged. Both the maximum r-hirudin plasma concentration and the area under the curve were increased. In addition, r-hirudin filtration by high-flux hemodialyzer membranes (polysulfone, AN69) was investigated 1) in the absence of aHAb, 2) in the presence of non-specific mouse antibodies, and 3) in the presence of three monoclonal aHAb. In the absence of aHAb, both hemodialyzers allowed for significant r-hirudin filtration. Non-specific mouse antibodies did not markedly affect r-hirudin filtration. By contrast, all three aHAb almost completely hindered r-hirudin filtration. aHAb varied in their capacity to neutralize r-hirudin. In conclusion, aHAb markedly alter the pharmacokinetics of r-hirudin leading to r-hirudin accumulation. In the presence of aHAb, hemofiltration does not allow for rapid reduction of r-hirudin concentration. aHAb are capable of modifying pharmacodynamics of r-hirudin. Close monitoring of aHAb-positive patients treated with r-hirudin is considered mandatory.

Keywords

Recombinant hirudin - anti-hirudin antibodies - neutralization - hemofiltration - pharmacokinetics

^* These authors contributed equally to this work

• References

• 1 Eriksson BI, Wille-Jorgensen P, Kälebo P. et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
• 2 Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429-38.
• 3 Greinacher A, Eichler P, Lubenow N. et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
• 4 Song X, Huhle G, Wang L. et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hiru-din. Circulation 1999; 100: 1528-32.
• 5 Huhle G, Hoffmann U, Song X. et al. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999; 106: 195-201.
• 6 Huhle G, Hoffmann U, Hoffmann I. et al. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb Res 2000; 99: 325-34.
• 7 Eichler P, Friesen HJ, Lubenow N. et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-8.
• 8 Huhle G, Liebe V, Hudek R. et al. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin’s plasma halflife. Thromb Haemost 2001; 85: 936-8.
• 9 Markwardt F, Fink G, Kaiser B. et al. Pharmacological survey of recombinant hiru-din. Pharmazie 1988; 43: 202-7.
• 10 Gygax D, Botta L, Ehrat M. et al. Immuno-assays in monitoring biotechnological drugs. Ther Drug Monit 1996; 18: 405-9.
• 11 Bauersachs RM, Lindhoff-Last E, Ehrly AM. et al. Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb Haemost 1999; 81: 323-4.
• 12 Friesen HJ, Kurrle R, Pünter J. et al. Development, characterization and application of anti-hirudin mouse monoclonal antibodies (abstract). Clin Chem 1996; S6: 180
• 13 European Standard 1283. Haemodialysers, haemodiafilters, haemofilters, haemoconcentrators and their extracorporeal circuits. Euro-pean Committee for Standardization 1996
• 14 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202.
• 15 Griessbach U, Sturzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-50.
• 16 Pedersen PC, Ostergaard PB, Hedner U. et al. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991; 61: 477-87.
• 17 Derendorf H. Pharmakokinetik: Einführung in die Theorie und Relevanz für die Arzneimitteltherapie [in German]. Stuttgart, Wissenschaftliche Verlagsgesellschaft 1987
• 18 Nowak G, Bucha E, Gööck Th. et al. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-15.
• 19 Bichler J, Baynes JW, Thorpe SR. Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochem J 1993; 296: 771-76.
• 20 Schlaeppi JM, Vekemans S, Rink H. et al. Preparation of monoclonal antibodies to hiru-din and hirudin peptides. A method for studying the hirudin—thrombin interaction. Eur J Biochem 1990; 188: 463-70.
• 21 Koch C, Whitechurch O, Cordier P. et al. Anti-hirudin monoclonal antibodies directed toward discontinuous epitopes of the hirudin amino-terminal and epitopes involving the carboxy-terminal hirudin amino acids. Anal Biochem 1993; 214: 301-12.
• 22 Yusuf S. The Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet 2002; 359: 294-302.